BNET Industries
Market Cap:$323.6M
Last Fiscal Year Sales:$33.5M
- Public
Dow Jones Description
Sinovac Biotech Ltd. specializes in the research, development, and commercialization of human vaccines for infectious diseases such as Hepatitis A and Hepatitis B, influenza, "SARS", avian influenza, etc. Sinovac is one of the leading emerging biotechnology companies in China. Working closely with Chinese public health officials, Sinovac focuses on manufacturing and marketing human-use vaccines and related products, and currently markets its Hepatitis A vaccine and Hepatitis A&B vaccine. Sinovac is the first company in the world to have been granted permission to conduct clinical trials for a vaccine to prevent SARS, and is the only one having completed phase I clinical trial on SARS vaccine. Sinovac aims to promote and develop Chinese biotech industry. By taking the advanced technologies and management mechanism, Sinovac focuses on manufacturing and marketing human-use vaccines and relative products, as well as technical consulting and services in order to make contribution to human health by improving people's preventive capabilities against serious diseases.
President, CEO, Secretary
Weidong YinNumber of Employees 305
Peer Companies
NAICS Code Biological Product (except Diagnostic) Manufacturing: 325414
Recent Events
-
Tivo Falls 6.8%; Basic Energy Surges
-
Sinovac Biotech Ltd announces formation of joint venture for human-use vaccine
-
Sinovac Receives Purchase Order from Shanghai Government to Supply Hepatitis A Vaccine HealiveR
-
Sinovac Reports Unaudited Third Quarter 2009 Financial Results
-
Sinovac Biotech Signs Agreement With Boryung Pharma To Collaborate On Marketing Efforts For Sinovac's H1N1...
-
Sinovac signs supply agreement with Boryung Pharmaceutical Company
-
China Biotech Takes an Important Step: FDA Approved Clinical Trials
-
Sinovac Biotech Ltd. SNVBF Reports Unaudited Second Quarter 2009 Financial Results
News & Analysis
Filter by
chinabio today and sinovac biotech ltd. - All News and Analysis
Sinovac Adds Vaccine Capacity by Forming JV
ChinaBio Today submits: Sinovac Biotech (NSDQ: SVA) announced a new Joint Venture, Sinovac Dalian Vaccine Technology Co., Ltd., that will research, develop and produce human vaccines. Sinovac will contribute its vaccine expertise and capital, while Dalian Jin Gang Group will throw in land use rights, manufacturing facilities and established...
Sinovac?s Q3 Soars
ChinaBio Today submits: Sinovac Biotech Ltd. (NSDQ: SVA) announced it has won a $3 million contract to supply its hepatitis A vaccine, Healive, to the Shanghai government. Sinovac said five companies vied for the contract, but Sinovac was chosen the sole supplier. Sinovac will supply Healive to Shanghai over...
Sinovac Set to Move Listing to NASDAQ
ChinaBio Today submits: Sinovac Biotech Ltd. SVA will move the home for its stock listing from the NYSE Amex to the NASDAQ Global Market. The reason given for the change was “greater liquidity.” Target day for the transfer is November 16. Although most NASDAQ companies use a four-letter symbol,...
Sinovac on Track to See Sizable Revenue from Flu Vaccines
ChinaBio Today submits: Sinovac Biotech SVA has received a very large order for 5.2 million doses of its H1N1 vaccine, Panflu.1. This is the third order Sinovac has received from various official China agencies, bringing the total to 11.5 million doses. Of the 5.2 million doses in the latest...
Sinovac Wins Approval for Swine Flu Vaccine in Mexico
ChinaBio Today submits: Sinovac Biotech Ltd. SVA has received a Certificate of Approval to distribute its swine flu vaccine, PANFLU.1, in Mexico, the first swine flu vaccine to be registered there. However, before vaccine can be shipped to Mexico, China’s government must approve the export. Sinovac is in the...
Sinovac Announces Second Large H1N1 Vaccine Order
ChinaBio Today submits: Sinovac Biotech Ltd. (NYSE: SVA) announced a second large H1N1 flu vaccine order from China’s national government. The new order is for an additional 3 million doses, which follows the original 3.3 million dose order of early September. Sinovac expects to deliver 4.5 million doses of...
Sinovac Wins OK to Produce H1N1 Vaccine
ChinaBio Today submits: Sinovac Biotech Ltd. (NYSE: SVA) has received an SFDA production license for Panflu.1, the company’s H1N1 vaccine. The SFDA approved the single-injection administration of the vaccine as sufficient to provide immunogenicity. As expected, the approval indicates the drug can be given to people from 3 to...
Sinovac's H1N1 Flu Vaccine Wins Experts' Recommendation
ChinaBio Today submits: Sinovac Biotech Ltd. SVA continued its barrage of H1N1 flu vaccine news by announcing that its product passed an experts’ evaluation organized by the SFDA. After spending August 30 and 31 looking at data from the vaccine’s recent clinical trial, the experts recommended approval of the...
Beijing Chooses Sinovac Biotech for Seasonal Flu Vaccine
ChinaBio Today submits: Sinovac Biotech (NYSE: SVA) (????????????) has been selected by the Public Health Bureau of Beijing to be one of four vaccine companies that will supply the city with seasonal flu vaccine for 2009. Sinovac will provide Beijing with its split viron vaccine, Anflu®. The city hopes...
Sinovac Claims Bragging Rights as First Vaccine Maker to Complete Swine Flu Test
ChinaBio Today submits: Sinovac Biotech Ltd. SVA reported that its swine flu (H1N1) vaccine was effective after a single dose. The seropositive rate, seroconvertive rate and GMT increasing multiple have reached the international criteria for vaccines, which indicates that Sinovac's H1N1 vaccine has good immunogenicity and offers protection. The...
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Weidong Yin | President, CEO, Secretary |
| Jinling Qin | Cfo |
| Changju Fu | Vice President |
| Changjun Fu | Vice President, Sales Dept & Marketing Dept & Business Dept |
| Jiansan Zhang | Vice General Manager |
| Nan Wang | Vice General Manager |
| Wang Jingning | Senior Manager, Manager of Human Resource Department |
| Xuejie Gong | Senior Manager |
| Cathy Mok | Director |
| Lo Yuk | Director |
| Cathy Mok Chup | Member |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Chup Hung Mok | Board of Directors |
| Lo Yuk Lam | Board of Directors |
| Mok Chup Hung | Board of Directors |
| Simon Anderson | Board of Directors |
| Xianping Wang | Board of Directors |
| Yuk Lam Lo | Board of Directors |
Mr. Yin is the President and CEO of Sinovac. He is also one of founders of Tangshan Yian and Sinovac Biotech Co., Ltd. He has been dedicated to hepatitis research for over 20 years starting as a doctor on epidemiology in Tangshan CDC (Hebei Province). He is credited with developing the intellectual property rights that led to the development of Sinovac's Hepatitis A Vaccine. Mr. Yin has been appointed to be the principal investigator by the Chinese Ministry of Science and echnology for many key governmental R&D programs such as "Inactivated Hepatitis A Vaccine R&D", "Inactivated SARS Vaccine R&D" and "New Human Influenza Vaccine (H5N1) R&D". Mr. Yin is instrumental in shaping the Chinese Ministry of Public Health's policy for prioritizing hepatitis as one of primary diseases to be negated by the country in the next five years. Dr Yin also serves some public obligations. He is the member of Chinese Foundation for Hepatitis Prevention and Control. He is academic consultant to various Chinese governmental organizations.
| Organization | Position | Status |
|---|---|---|
| Sinovac Biotech, Ltd. | President, CEO, Secretary | Current |
| Sinovac Biotech, Ltd. | Board of Directors | Current |
| Sinovac Biotech, Ltd. | General Manager of Sinovac Biotech Co., Ltd. CEO | Former |
| Organization | Position | Status |
|---|---|---|
| Sinovac Biotech, Ltd. | Cfo | Current |
| Organization | Position | Status |
|---|---|---|
| Sinovac Biotech, Ltd. | Vice President | Current |
| Organization | Position | Status |
|---|---|---|
| Sinovac Biotech, Ltd. | Vice President, Sales Dept & Marketing Dept & Business Dept | Current |
Mr. Zhang has had sophisticated training courses on Biological product manufacturing management and quality control in Holland and received training on biological product manufacturing management and quality control at Merck. He fully understands European GMP standards, which was used into manufacturing workshop construction of inactivated hepatitis A vaccine and split flu vaccine, which guides the production management and quality control of Sinovac to meet international standards.
| Organization | Position | Status |
|---|---|---|
| Sinovac Biotech, Ltd. | Vice General Manager | Current |
| Organization | Position | Status |
|---|---|---|
| Sinovac Biotech, Ltd. | Vice General Manager | Current |
Ms. Wang has over 10 years of experience in the field of business development, project research and registration management,. working with China Bioway Biotech Group and Shenzhen Kexing Biological Product Co., Ltd. She has conducted studies on development strategy of biological enterprises. And at the same time she knows well about government policy relating to drug R&D and registration. She also holds very good relationship with related government officials.
| Organization | Position | Status |
|---|---|---|
| Sinovac Biotech, Ltd. | Senior Manager, Manager of Human Resource Department | Current |
| Organization | Position | Status |
|---|---|---|
| Sinovac Biotech, Ltd. | Senior Manager | Current |
| Organization | Position | Status |
|---|---|---|
| Sinovac Biotech, Ltd. | Director | Current |
| Organization | Position | Status |
|---|---|---|
| Sinovac Biotech, Ltd. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Sinovac Biotech, Ltd. | Director | Current |
| Organization | Position | Status |
|---|---|---|
| Sinovac Biotech, Ltd. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Sinovac Biotech, Ltd. | Board of Directors | Current |
Mr. Simon Anderson has been a Director of the Company since July 23, 2004. Mr. Anderson has been a partner and Vice President of MCSI Consulting Services Inc. from 1996 to present. Mr. Anderson is a Chartered Accountant and a Chartered Business Valuator and from 1994 to 1996 was a partner with BDO Dunwoody, an international accounting and consulting firm, where he specialized in mergers, acquisitions and valuations. Mr. Anderson was admitted as a member of the Institute of Chartered Accountants in British Columbia in 1986. He has also been a member of the Canadian Institute of Charter Business Valuators since 1990. In addition, Mr. Anderson is a director and/or Chief Financial Officer of four other public companies. Mr. Lo Yuk Lam (age 58) is a director nominee and is presently the Vice President of PerkinElmer Life and Analytical Sciences, Pacific Rim, the Chairman of the Chinese Manufacturers' Association of Hong Kong Industry Technology Committee, and the Director of the Chinese Manufacturers' Association of Hong Kong. Professor Lo was the Chairman of the Innovation and Technology Fund (Biotechnology Projects) Vetting Committee, HKSAR, and of the Biotechnology Committee, Industry & Technology Development Council, HKSAR. He was also the Director of the Hong Kong Applied R&D Fund Co., Ltd., HKSAR. Prof. Lo was heavily involved in several committees of the Industry Department of the HKSAR Government. Prof. Lo has been awarded the Honorary Fellow by the Hong Kong University of Science and Technology and the Honorary Chairman of the City University Committee of Co-operative Education Centre. Prof. Lo has extensively served the societies of Greater China. He is currently a Member of the Advisory Committee of the World Trade Centre Association (Hong Kong), an Adjunct Professor of the Chinese University of Hong Kong, the Special Advisor of the Hong Kong University of Science & Technology (HKUST), a Committee Member of the Biotechnology Research Institute (BRI) of HKUST, and a Member of the Advisory Committee of the City University of Hong Kong and the Hong Kong Polytechnic University. In Mainland China, Prof. Lo is the Consultant of the Economic Bureau, Changchun, a Member of the Advisory Committee of the Shenzhen Municipal Science and Technology Bureau, the Honorary Consultant of the Beijing Medical University, the Honorary Professor of Chengdu University of TCM and the Visiting Professor of the Xiamen University China and the Shanghai Jiao Tong University.
| Organization | Position | Status |
|---|---|---|
| Chinese University of Hong Kong | Adjunct Professor | Current |
| Sinovac Biotech, Ltd. | Board of Directors | Current |
| Bdo Dunwoody Llp | Partner | Former |
Mr. Xianping Wang (Age 47) is a director nominee and has been the President and CEO of Xinhua China Ltd. since September 2004, which is a reporting issuer and is listed on the National Association of Securities Dealers Over-the-Counter Bulletin Board having the symbol "XHUA". He is also President of Asia-Durable (Beijing) Investments Co., Ltd. since 2002, the President of Beijing New Fortune Investment Co., Ltd. from 1997-2002, and General Manager of Beijing Fuhua Constructions and Development Co., Ltd. from 1992-1997. Mr. Wang has obtained two university degrees, one was an Engineer Bachelor Degree from Navy Engineering Institute, and the other one was an Economy Master Degree from Tsinghua University. After graduation from university, Mr. Wang dedicated diversity industries, such as bio-medicine, healthy industry, construction projects, investment consultation and real estate development as well as other related industries. Since 1993, he has participated in varied real estate investment projects in China, managing the development of Fuhua Mansion, Meihui Mansion and Jinhua Garden, including others, with a total marketable area of 600,000 square meters.
| Organization | Position | Status |
|---|---|---|
| Sinovac Biotech, Ltd. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Sinovac Biotech, Ltd. | Board of Directors | Current |
Ms. Cathy Mok Chup Hung ("Mok") (age 48) is a director nominee and is currently the Financial Controller of Zero Spot Laundry Service Private Limited where she is responsible for the financial affairs of that company and also leads the human resource management function. Prior to joining Zero Spot Laundry Service Private Limited, Mok had more than 28 years of banking experience. Mok joined Bank of China, Singapore Branch in January 2002. During that period, she lead the Internal Audit and Treasury Settlements functions. Mok was also a member of the bank's Assets and Liabilities Management Committee, Prevention of Money Laundering Committee and Business Continuity Management Committee. Prior to joining Bank of China, Mok began her career with The Kwangtung Provincial Bank Singapore Branch. During that period, she worked in the retail banking division. Mok was also responsible for setting up the Kwangtung Provincial Bank's Treasury Department. From 1992 to 2001, being the senior management member of the bank, she had oversight responsibilities in accounting, treasury settlements, human resource management and credit management functions. In addition, Mok was a member of Kwangtung Provincial Bank's Credit Committee and Prevention of Money Laundering Committee. Mok holds a Master of Business Administration from the National University of Singapore.
| Organization | Position | Status |
|---|---|---|
| Sinovac Biotech, Ltd. | Member | Current |
| Sinovac Biotech, Ltd. | Director | Current |
| National University of Singapore | Master of Business Administration | Former |
Executive News
-
China's Vice Premier, Li Keqiang, Visits Sinovac to Inspect H1N1 Vaccine Production...
-
Sinovac Reports Unaudited First Quarter 2009 Financial Results
| Volume | 2,532,130 |
| Shares Outstanding | 42.5M |
| Market Cap | 323.6M |
| Year High | 12.50 |
| Year Low | 0.75 |
| Earnings Per Share | 0.32 |
| P/E Ratio | 23.75 |
| Dividend | 0.00 |
| Yield | 0.00 |
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes


